Objective To report the outcomes of intra-and extra-peritoneal robot-assisted radical prostatectomy(RARP)and robot-assisted radical cystectomy(RARC)with Hugo™robot-assisted surgery(RAS)system(Medtronic,Minneapolis,MN,...Objective To report the outcomes of intra-and extra-peritoneal robot-assisted radical prostatectomy(RARP)and robot-assisted radical cystectomy(RARC)with Hugo™robot-assisted surgery(RAS)system(Medtronic,Minneapolis,MN,USA).Methods Data of twenty patients who underwent RARP and one RARC at our institution between February 2022 and January 2023 were reported.The primary endpoint of the study was to report the surgical setting of Hugo™RAS system to perform RARP and RARC.The secondary endpoint was to assess the feasibility of RARP and RARC with this novel robotic platform and report the outcomes.Results Seventeen patients underwent RARP with a transperitoneal approach,and three with an extraperitoneal approach;and one patient underwent RARC with intracorporeal ileal conduit.No intraoperative complications occurred.Median docking and console time were 12(interquartile range[IQR]7-16)min and 185(IQR 177-192)min for transperitoneal RARP,15(IQR 12-17)min and 170(IQR 162-185)min for extraperitoneal RARP.No intraoperative complications occurred.One patient submitted to extraperitoneal RARP had a urinary tract infection in the postoperative period that required an antibiotic treatment(Clavien-Dindo Grade 2).In case of transperitoneal RARP,two minor complications occurred(one pelvic hematoma and one urinary tract infection;both Clavien-Dindo Grade 2).Conclusion Hugo™RAS system is a novel promising robotic platform that allows to perform major oncological pelvic surgery.We showed the feasibility of RARP both intra-and extra-peritoneally and RARC with intracorporeal ileal conduit with this novel platform.展开更多
Background:Lower urinary tract symptoms(LUTS)and pain are clinically relevant problems after transurethral resection(TURBT)of nonmuscle-invasive bladder cancer.Although intravesical instillation of hyaluronic acid has...Background:Lower urinary tract symptoms(LUTS)and pain are clinically relevant problems after transurethral resection(TURBT)of nonmuscle-invasive bladder cancer.Although intravesical instillation of hyaluronic acid has already been proven to be a valid treatment for storage LUTS and pain in patients with inflammatory bladder syndrome,its effcacy in patients who undergo TURBT is unknown.This study aimed to present the results of a prospective,randomized,controlled,clinical pilot study on the safety and clinical performance of Hydeal Cyst(Fidia Farmaceutici S.p.A.,Italy),a device formulated to provide progressive,long-lasting intravesical release of hyaluronic acid.Materials and methods:Adults diagnosed with nonmuscle-invasive bladder cancer and scheduled for TURBT were included and underwent 4 visits up to 25 days after TURBT.Of the 47 patients who completed the investigation,25 participants received 2 postoperative intravesical instillations with Hydeal Cyst.The effcacy of Hydeal Cyst on storage LUTS,pain,urinary symptoms,and patients'quality of life was evaluated using validated questionnaires.Results:Although the overall LUTS were similar in the 2 experimental groups,lower micturition frequency and fewer daytime micturitions were observed in patients treated with Hydeal Cyst.These patients also showed a signifcant reduction in pain(p=0.03)3 days after catheter removal and better quality of life at the end of the study.The device was well tolerated,with no treatment-emergent adverse events of severe intensity.Conclusion:The results from this pilot study indicate a clinically meaningful improvement of symptoms after 2 instillations of Hydeal Cyst,supporting this intervention as a potentially effective treatment for LUTS and pain after TURBT.展开更多
文摘Objective To report the outcomes of intra-and extra-peritoneal robot-assisted radical prostatectomy(RARP)and robot-assisted radical cystectomy(RARC)with Hugo™robot-assisted surgery(RAS)system(Medtronic,Minneapolis,MN,USA).Methods Data of twenty patients who underwent RARP and one RARC at our institution between February 2022 and January 2023 were reported.The primary endpoint of the study was to report the surgical setting of Hugo™RAS system to perform RARP and RARC.The secondary endpoint was to assess the feasibility of RARP and RARC with this novel robotic platform and report the outcomes.Results Seventeen patients underwent RARP with a transperitoneal approach,and three with an extraperitoneal approach;and one patient underwent RARC with intracorporeal ileal conduit.No intraoperative complications occurred.Median docking and console time were 12(interquartile range[IQR]7-16)min and 185(IQR 177-192)min for transperitoneal RARP,15(IQR 12-17)min and 170(IQR 162-185)min for extraperitoneal RARP.No intraoperative complications occurred.One patient submitted to extraperitoneal RARP had a urinary tract infection in the postoperative period that required an antibiotic treatment(Clavien-Dindo Grade 2).In case of transperitoneal RARP,two minor complications occurred(one pelvic hematoma and one urinary tract infection;both Clavien-Dindo Grade 2).Conclusion Hugo™RAS system is a novel promising robotic platform that allows to perform major oncological pelvic surgery.We showed the feasibility of RARP both intra-and extra-peritoneally and RARC with intracorporeal ileal conduit with this novel platform.
文摘Background:Lower urinary tract symptoms(LUTS)and pain are clinically relevant problems after transurethral resection(TURBT)of nonmuscle-invasive bladder cancer.Although intravesical instillation of hyaluronic acid has already been proven to be a valid treatment for storage LUTS and pain in patients with inflammatory bladder syndrome,its effcacy in patients who undergo TURBT is unknown.This study aimed to present the results of a prospective,randomized,controlled,clinical pilot study on the safety and clinical performance of Hydeal Cyst(Fidia Farmaceutici S.p.A.,Italy),a device formulated to provide progressive,long-lasting intravesical release of hyaluronic acid.Materials and methods:Adults diagnosed with nonmuscle-invasive bladder cancer and scheduled for TURBT were included and underwent 4 visits up to 25 days after TURBT.Of the 47 patients who completed the investigation,25 participants received 2 postoperative intravesical instillations with Hydeal Cyst.The effcacy of Hydeal Cyst on storage LUTS,pain,urinary symptoms,and patients'quality of life was evaluated using validated questionnaires.Results:Although the overall LUTS were similar in the 2 experimental groups,lower micturition frequency and fewer daytime micturitions were observed in patients treated with Hydeal Cyst.These patients also showed a signifcant reduction in pain(p=0.03)3 days after catheter removal and better quality of life at the end of the study.The device was well tolerated,with no treatment-emergent adverse events of severe intensity.Conclusion:The results from this pilot study indicate a clinically meaningful improvement of symptoms after 2 instillations of Hydeal Cyst,supporting this intervention as a potentially effective treatment for LUTS and pain after TURBT.
